{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:37:51Z","timestamp":1793417871727,"version":"4.5.0"},"reference-count":47,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,5,31]],"date-time":"2020-05-31T00:00:00Z","timestamp":1590883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Predictive biomarkers of response to chemotherapy plus antiangiogenic for metastatic colorectal cancer (mCRC) are lacking. The objective of this study was to test the prognostic role of splenomegaly on baseline CT scan. Methods: This study is a sub-study of PRODIGE-9 study, which included 488 mCRC patients treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab in first line. The association between splenic volume, and PFS and OS was evaluated by univariate and multivariable Cox analyses. The relation between circulating monocytic Myeloid derived suppressor cells (mMDSC) and splenomegaly was also determined. Results: Baseline splenic volume &gt; 180 mL was associated with poor PFS (median PFS = 9.2 versus 11.1 months; log-rank p = 0.0125), but was not statistically associated with OS (median OS = 22.6 versus 28.5 months; log-rank p = 0.1643). The increase in splenic volume at 3 months had no impact on PFS (HR 0.928; log-rank p = 0.56) or on OS (HR 0.843; log-rank p = 0.21). Baseline splenic volume was positively correlated with the level of baseline circulating mMDSC (r = 0.48, p-value = 0.031). Conclusion: Baseline splenomegaly is a prognostic biomarker in patients with mCRC treated with FOLFIRI and bevacizumab, and a surrogate marker of MDSC accumulation.<\/jats:p>","DOI":"10.3390\/cancers12061429","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T09:19:27Z","timestamp":1591089567000},"page":"1429","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma"],"prefix":"10.3390","volume":"12","author":[{"given":"Julie","family":"Niogret","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Georges Fran\u00e7ois Leclerc Cancer Center-UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France"},{"name":"Department of Medical Oncology, University of Burgundy-Franche-Comt\u00e9, 7 Boulevard Jeanne d\u2019Arc, 21000 Dijon, France"},{"name":"INSERM U1231, 7 Boulevard Jeanne d\u2019Arc, 21000 Dijon, France"},{"name":"Platform of Transfer in Cancer Biology, Georges Fran\u00e7ois Leclerc Cancer Center\u2014UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeric","family":"Limagne","sequence":"additional","affiliation":[{"name":"Platform of Transfer in Cancer Biology, Georges Fran\u00e7ois Leclerc Cancer Center\u2014UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Thibaudin","sequence":"additional","affiliation":[{"name":"Platform of Transfer in Cancer Biology, Georges Fran\u00e7ois Leclerc Cancer Center\u2014UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Blanc","sequence":"additional","affiliation":[{"name":"Methodology, Data-Management, and Biostatistics Unit, Georges Fran\u00e7ois Leclerc Cancer Center\u2014UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Bertaut","sequence":"additional","affiliation":[{"name":"Methodology, Data-Management, and Biostatistics Unit, Georges Fran\u00e7ois Leclerc Cancer Center\u2014UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Le Malicot","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Burgundy-Franche-Comt\u00e9, 7 Boulevard Jeanne d\u2019Arc, 21000 Dijon, France"},{"name":"F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive, EPICAD INSERM U1231, 7 Boulevard Jeanne d\u2019Arc, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, European Hospital, 6 Rue D\u00e9sir\u00e9e Clary, 13003 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Caroli-Bosc","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Center, 4 Rue Larrey, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Audemar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, C\u00f4te Basque Hospital Center, 13 Avenue de l\u2019Interne Jacques Loeb, 64100 Bayonne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Center, 4 Boulevard Hauterive, 64000 Pau, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Sarda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saintonge Hospital Center, 11 Boulevard Ambroise Par\u00e9, 17100 Saintes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lombard-Bohas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Edouard Herriot Hospital, HCL, 5 Place d\u2019Arsonval, 69003 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Locher","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Est-Francilien Great Hospital, 6-8 Rue Saint-Fiacre, 77100 Meaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Carreiro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Internal medicine, Hospital Center, 100 Rue L\u00e9on Cladel, 82000 Montauban, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Legoux","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology and Digestive Oncology, Regional Hospital Center, 14 Avenue de l\u2019H\u00f4pital, 45100 Orl\u00e9ans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Luc","family":"Etienne","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CARIO, C\u00f4tes d\u2019Armor Private Hospital, 10 Rue Fran\u00e7ois Jacob, 22190 Plerin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Baconnier","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, Annecy Genevois Hospital Center, 1 Avenue de l\u2019H\u00f4pital, 74374 Pringy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Porneuf","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Yves Le Foll Hospital Center, 10 Rue Marcel Proust, 22000 Saint-Brieuc, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8834-6927","authenticated-orcid":false,"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Center Saint Louis, APHP, 1 Avenue Claude Vellefaux, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5465-8305","authenticated-orcid":false,"given":"Francois","family":"Ghiringhelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Georges Fran\u00e7ois Leclerc Cancer Center-UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France"},{"name":"Department of Medical Oncology, University of Burgundy-Franche-Comt\u00e9, 7 Boulevard Jeanne d\u2019Arc, 21000 Dijon, France"},{"name":"INSERM U1231, 7 Boulevard Jeanne d\u2019Arc, 21000 Dijon, France"},{"name":"Platform of Transfer in Cancer Biology, Georges Fran\u00e7ois Leclerc Cancer Center\u2014UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/annonc\/mds236","article-title":"ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making","volume":"23","author":"Schmoll","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_4","first-page":"iii1","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Cervantes","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Cervantes","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","article-title":"Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared with Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest","volume":"25","author":"Falcone","year":"2007","journal-title":"JCO"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1634\/theoncologist.2011-0249","article-title":"First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study","volume":"17","author":"Sastre","year":"2012","journal-title":"Oncologist"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S1470-2045(15)00042-X","article-title":"Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): A randomised, non-inferiority, open-label, phase 3 trial","volume":"16","author":"Graeven","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab\u2013FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer","volume":"33","author":"Lenz","year":"2015","journal-title":"JCO"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer: Metastatic Pattern in BRAF Mutant CRC","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E\u2013Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: A systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2217\/pgs.10.95","article-title":"Irinotecan pharmacogenomics","volume":"11","author":"Marsh","year":"2010","journal-title":"Pharmacogenomics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FPC.0000000000000024","article-title":"PharmGKB summary: Very important pharmacogene information for UGT1A1","volume":"24","author":"Barbarino","year":"2014","journal-title":"Pharmacogenet. Genom."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","article-title":"Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: Results from two randomized first-line panitumumab studies","volume":"28","author":"Boeckx","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.18.02258","article-title":"Impact of Consensus Molecular Subtype on Survival in Patients with Metastatic Colorectal Cancer: Results from CALGB\/SWOG 80405 (Alliance)","volume":"37","author":"Lenz","year":"2019","journal-title":"JCO"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/annonc\/mdy410","article-title":"The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: Molecular analysis of the AGITG MAX clinical trial","volume":"29","author":"Mooi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1093\/annonc\/mdz387","article-title":"Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial","volume":"30","author":"Stintzing","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2017.75.2931","article-title":"Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)","volume":"36","author":"Aparicio","year":"2018","journal-title":"JCO"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41416-020-0735-8","article-title":"Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: Analysis from PRODIGE 9 trial","volume":"122","author":"Aparicio","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2018-316407","article-title":"Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab","volume":"69","author":"Dohan","year":"2020","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1111\/j.1582-4934.2009.00685.x","article-title":"Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells","volume":"13","author":"Stewart","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1158\/0008-5472.CAN-15-3164","article-title":"Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX\u2013Bevacizumab Drug Treatment Regimen","volume":"76","author":"Limagne","year":"2016","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhang, B., Wang, Z., Wu, L., Zhang, M., Li, W., Ding, J., Zhu, J., Wei, H., and Zhao, K. (2013). Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057114"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin\u2013cyclophosphamide chemotherapy","volume":"58","author":"Salem","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/879897","article-title":"Increased Levels of Granulocytic Myeloid-Derived Suppressor Cells in Peripheral Blood and Tumour Tissue of Pancreatic Cancer Patients","volume":"2014","author":"Khaled","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s40425-019-0734-6","article-title":"Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3","volume":"7","author":"Trovato","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00262-011-1028-0","article-title":"Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13","volume":"60","author":"Gabitass","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1158\/2326-6066.CIR-15-0298","article-title":"Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients","volume":"4","author":"Tada","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Aarnink, A., Richard, C., Truntzer, C., Vincent, J., Bengrine, L., Vienot, A., Borg, C., and Ghiringhelli, F. (2018). Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma. Oncotarget, 9.","DOI":"10.18632\/oncotarget.25424"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/annonc\/mdf034","article-title":"Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients","volume":"13","author":"Cunningham","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1634\/theoncologist.2011-0039","article-title":"Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study","volume":"16","author":"Chibaudel","year":"2011","journal-title":"Oncologist"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s003300050145","article-title":"Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus","volume":"7","author":"Prassopoulos","year":"1997","journal-title":"Eur. Radiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00262-016-1953-z","article-title":"Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients","volume":"66","author":"Jordan","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","article-title":"Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells","volume":"66","author":"Condamine","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immu."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00262-013-1475-x","article-title":"Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients","volume":"62","author":"Jordan","year":"2013","journal-title":"Cancer Immunol. Immuno."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/exd.12336","article-title":"Increased frequencies of CD11b + CD33 + CD14 + HLA-DR low myeloid-derived suppressor cells are an early event in melanoma patients","volume":"23","author":"Rudolph","year":"2014","journal-title":"Exp. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.dld.2015.01.146","article-title":"FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9\u2014FFCD 0802)","volume":"47","author":"Aparicio","year":"2015","journal-title":"Dig. Liver. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Budczies, J., Klauschen, F., Sinn, B.V., Gy\u0151rffy, B., Schmitt, W.D., Darb-Esfahani, S., and Denkert, C. (2012). Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0051862"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1429\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:34:17Z","timestamp":1760175257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,31]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cancers12061429"],"URL":"https:\/\/doi.org\/10.3390\/cancers12061429","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,31]]}}}